Nicotinamide

Generic Name: Nicotinamide

Brand Names: Alertonic, Fortaplex, Infuvite, Infuvite Pediatric, Mvc-fluoride, Mvi Pediatric, Natafort, Neo-bex, Nicomide, Pregvit, Tandem Plus

Drug Type: Small Molecule

Chemical Formula: C_₆H_₆N_₂O

CAS Number: 98-92-0

Unique Ingredient Identifier: 25X51I8RD4

Background: An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.

Indication: 用于防治糙皮病等烟酸缺乏病，也用于防治心脏传导阻滞。

Associated Conditions: Gastrointestinal insufficiency, Hepatic Insufficiency, Macrocytic anemia, Secondary anemia, Vitamin Deficiency, Severe debilitation

Associated Therapies: Dietary and Nutritional Therapies, Nutritional supplementation, Dietary supplementation

Clinical Trials

Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM)

Phase 1

Completed

Conditions: Pharmacokinetic
Safety Issues

Interventions: Drug: controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)
Drug: Immediate-release nicotinamide (SAD)
Drug: Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD)
Drug: Placebo Immediate-release nicotinamide (SAD)

First Posted Date: 2022-02-28

Last Posted Date: 2022-11-08

Lead Sponsor: University Hospital Schleswig-Holstein

Target Recruit Count: 49

Registration Number: NCT05258474

Locations: 🇩🇪
University Medical Center Schleswig-Holstein, Kiel, Germany

Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19

Not Applicable

Completed

Conditions: Lymphopenia
Covid19

Interventions: Drug: nicotinamide

First Posted Date: 2021-06-02

Last Posted Date: 2021-11-08

Lead Sponsor: Qiang Hu

Target Recruit Count: 24

Registration Number: NCT04910230

Locations: 🇨🇳
General Hospital of Northern Theater Command, Shenyang, Liaoning, China

NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

Phase 2

Active, not recruiting

Conditions: Ataxia Telangiectasia

Interventions: Drug: Nicotinamide ribonucleoside

First Posted Date: 2021-05-04

Last Posted Date: 2022-08-17

Lead Sponsor: University Hospital, Akershus

Target Recruit Count: 13

Registration Number: NCT04870866

Locations: 🇳🇴
Hilde Loge Nilsen, Lørenskog, Norway
🇳🇴
Oslo University Hospital, Oslo, Norway

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Placebo
Drug: Nicotinamide

First Posted Date: 2021-04-14

Last Posted Date: 2024-08-16

Lead Sponsor: University of Utah

Target Recruit Count: 86

Registration Number: NCT04844528

Locations: 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States

Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients

Early Phase 1

Completed

Conditions: Actinic Keratoses

Interventions: Drug: Oral Nicotinamide

First Posted Date: 2021-04-13

Last Posted Date: 2021-04-22

Lead Sponsor: Rhode Island Hospital

Target Recruit Count: 30

Registration Number: NCT04843553

Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause

Not Applicable

Completed

Conditions: Menopause

Interventions: Drug: BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)

First Posted Date: 2021-04-12

Last Posted Date: 2021-11-18

Lead Sponsor: University of South Alabama

Target Recruit Count: 40

Registration Number: NCT04841499

Locations: 🇺🇸
University of South Alabama, Mobile, Alabama, United States

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

Phase 2

Recruiting

Conditions: Ischemia Reperfusion Injury
Myocardial Injury
Acute Kidney Injury

Interventions: Drug: Niacinamide
Drug: Placebo

First Posted Date: 2021-02-11

Last Posted Date: 2025-03-12

Lead Sponsor: Kaiser Permanente

Target Recruit Count: 304

Registration Number: NCT04750616

Locations: 🇺🇸
Kaiser Permanente San Francisco Medical Center, San Francisco, California, United States

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

Phase 2

Completed

Conditions: Treatment-resistant Depression

Interventions: Drug: Psilocybin
Drug: Nicotinamide

First Posted Date: 2020-12-17

Last Posted Date: 2025-01-20

Lead Sponsor: Central Institute of Mental Health, Mannheim

Target Recruit Count: 144

Registration Number: NCT04670081

Locations: 🇩🇪
Central Institute of Mental Health (CIMH), Mannheim, Germany
🇩🇪
Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy, Berlin, Germany

International Trial of Efficacy of Cytoflavin in Head Trauma

Phase 3

Completed

Conditions: Head Trauma,Closed

Interventions: Drug: Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)
Drug: Placebo

First Posted Date: 2020-11-17

Last Posted Date: 2025-04-18

Lead Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Target Recruit Count: 166

Registration Number: NCT04631484

Locations: 🇰🇿
West Kazakhstan Medical University named after. M. Ospanov, Aktobe, Kazakhstan
🇷🇺
Ivanovskaya Regional Clinical Hospital, Ivanovo, Russian Federation
🇷🇺
City Clinical Hospital No. 67 named after L.A. Vorokhobov, Moscow, Russian Federation

and more 5 locations

Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants

Phase 2

Recruiting

Conditions: Inadequate Milk Production
Preterm Birth

Interventions: Drug: Nicotinamide riboside chloride
Drug: Placebo

First Posted Date: 2020-11-04

Last Posted Date: 2025-04-04

Lead Sponsor: University of California, Davis

Target Recruit Count: 32

Registration Number: NCT04614714

Locations: 🇺🇸
UC Davis Department of Food Science and Technology, Sacramento, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy